Apr 5 |
Protara Therapeutics jumps 23% on $45M oversubscribed private financing
|
Apr 5 |
Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing
|
Apr 5 |
Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition
|
Apr 5 |
Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC
|
Mar 13 |
Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|
Feb 28 |
Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
|
Feb 22 |
Protara: A Bombed Out Biotech With A Very Positive Skew
|
Feb 17 |
We're Keeping An Eye On Protara Therapeutics' (NASDAQ:TARA) Cash Burn Rate
|
Jan 31 |
Protara Therapeutics to Participate in Upcoming Investor Conferences
|
Nov 30 |
Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology
|